Publisher: Karger
E-ISSN: 1423-0313|85|1|1-17
ISSN: 0031-7012
Source: Pharmacology, Vol.85, Iss.1, 2009-11, pp. : 1-17
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Most neurodegenerative diseases share several clinical, genetic and pathophysiological features, and an irreversible evolution as well. They are characterized by an endogenous production of abnormal proteins called amyloid proteins (AP), which are not hydrosoluble, form depots, and are only partly cleared by autophagy and the ubiquitin-protease system. Despite their different structures, they are probably generated by a common pathological pathway, a misfolding process. This hypothesis suggests a common pharmacological approach, which can consist of either the blockade of the misfolding process, the elimination of AP or both. The currently validated treatments are mostly palliative ones, trying to supplant the function of destroyed neurons. New trends involve the regulation of the cerebral cholesterol metabolism and the preservation of neuron mitochondrial functions. Special attention is given to already marketed drugs used for other indications, which are also able to act on neurodegeneration.
Related content
By Herrera-Arozamena Clara Martí-Marí Olaia Estrada Martín de la Fuente Revenga Mario Rodríguez-Franco María Isabel
Molecules, Vol. 21, Iss. 9, 2016-09 ,pp. :
Zinc, Carnosine, and Neurodegenerative Diseases
By Kawahara Masahiro Tanaka Ken-ichiro Kato-Negishi Midori
Nutrients, Vol. 10, Iss. 2, 2018-01 ,pp. :
The Function of Autophagy in Neurodegenerative Diseases
By Kiriyama Yoshimitsu Nochi Hiromi
International Journal of Molecular Sciences, Vol. 16, Iss. 11, 2015-11 ,pp. :